Dovitinib lactate
Dovitinib lactate (TKI-258) is a potent small molecule inhibitor targeting Fibroblast Growth Factor Receptor 3 (FGFR3) with an IC50 of 5 nM. It is widely used in preclinical research to investigate FGFR3-driven signaling pathways in vitro and has demonstrated antitumor activity in various in vivo cancer models, including bladder cancer and multiple myeloma.
Product Specifications
CAS Number
692737-80-7
Product Name Alternative
Inhibitor, Fibroblast growth factor receptor, FGFR, FGFR3, Fms like tyrosine kinase 3, FLT3, Platelet-derived growth factor receptor, inhibit, Dovitinib, Dovitinib lactate, Dovitinib Lactate, cKit, c-Kit, Cluster of differentiation antigen 135, CD135, CHIR258, CHIR-258, CHIR258 Lactate, CHIR-258 Lactate, CHIR-258 lactate, CHIR 258 Lactate, CHIR 258, CD117, Vascular endothelial growth factor receptor, VEGFR, TKI 258, TKI 258 Lactate, TKI258, TKI-258, TKI258 Lactate, TKI-258 lactate, TKI-258 Lactate, PDGFR, SCFR
Field of Research
Cardiovascular Research, Signal Transduction
Purity
98.44% (May vary between batches)
Solubility
DMSO:25 mg/mL (51.81 mM)
Smiles
CC (O) C (O) =O.CN1CCN (CC1) c1ccc2nc ([nH]c2c1) -c1c (N) c2c (F) cccc2[nH]c1=O
Molecular Formula
C24H27FN6O4
Molecular Weight
482.51
Storage Conditions
-20°C
Notes
For research use only.
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
GTR15178954 1 Vial
Lentiviral mouse Nrbp1 shRNA (UAS) - Lentiviral mouse Nrbp1 shRNA (UAS, GFP) plasmid
Sign In for Pricing
View Details 